Femasys (NASDAQ:FEMY) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen cut shares of Femasys (NASDAQ:FEMY) from a sell rating to a strong sell rating in a research report released on Sunday morning,Wall Street Zen reports.

Several other equities research analysts have also commented on FEMY. Maxim Group cut their price target on shares of Femasys to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Weiss Ratings downgraded shares of Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 17th. Finally, Lake Street Capital dropped their price objective on Femasys to $10.00 and set a “buy” rating on the stock in a report on Tuesday, August 18th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $50.00.

Femasys Price Performance

FEMY stock opened at $1.43 on Friday. The stock has a market cap of $11.98 million, a price-to-earnings ratio of -0.41 and a beta of -2.13. Femasys has a fifty-two week low of $1.25 and a fifty-two week high of $22.20. The company has a quick ratio of 0.55, a current ratio of 2.14 and a debt-to-equity ratio of 0.89. The business has a 50 day moving average price of $2.06 and a 200 day moving average price of $5.78.

Femasys (NASDAQ:FEMY) last released its quarterly earnings data on Friday, August 14th. The company reported ($1.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02). Femasys had a negative return on equity of 225.97% and a negative net margin of 534.36%. The company had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.73 million.

Femasys Company Profile

Femasys Inc. is a biotechnology and medical device company focused on developing and commercializing products for women’s health. The company’s portfolio is centered on solutions for permanent birth control, fertility evaluation and treatment, and related gynecological procedures. Femasys’ products include FemVue, a device used with saline and air to assess fallopian tube patency during fertility evaluations. The company is also developing FemBloc, a non-surgical, investigational permanent birth control system designed for placement through the fallopian tubes.